Nuvation Bio (NUVB) Income towards Parent Company (2020 - 2026)

Nuvation Bio (NUVB) has reported Income towards Parent Company for 7 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 110.14% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at -$146.0 million (up 75.92% YoY), while the FY2025 annual figure was -$204.6 million, up 63.97% from the prior year.
• Income towards Parent Company advanced to $5.4 million in Q1 2026 per NUVB's latest filing, from -$36.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $5.4 million in Q1 2026 and bottomed at -$462.5 million in Q2 2024.
• Historically, Income towards Parent Company has averaged -$55.7 million across 5 years, with a median of -$27.2 million in 2022.
• Annual changes were most pronounced in 2024 — Income towards Parent Company slumped 2140.76% — and 2026, when it jumped 110.14%.
• Nuvation Bio's Income towards Parent Company stood at -$20.8 million in 2022, then jumped by 33.86% to -$13.8 million in 2023, then slumped by 258.63% to -$49.4 million in 2024, then gained by 25.99% to -$36.6 million in 2025, then surged by 114.75% to $5.4 million in 2026.
• Business Quant data shows NUVB's Income towards Parent Company at $5.4 million in Q1 2026, -$36.6 million in Q4 2025, and -$55.8 million in Q3 2025.